HROW Harrow Health


From Benzinga Pro
Looking Into Harrow Health's Return On Capital Employed
22 Sep 21
According to Benzinga Pro, during Q2, Harrow Health (NASDAQ:HROW) earned $4.17 million, a 72.13% increase from the preceding quarter. Harrow Health also posted a total of $18.13 million in sales, a 17.43% increase since Q1.
Harrow Health Reports Provides $13.5M Senior Secured Loan To Melt Pharma
2 Sep 21
News, Financing
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, and Melt
Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum
18 Aug 21
Biotech, M&A, News, Health Care, General
Harrow Health Acquires US And Canadian Rights To MAQ-100 From Wakamoto Pharmaceutical; Terms Not Disclosed
18 Aug 21
Biotech, General
Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights
Harrow Health: Q2 Earnings Insights
10 Aug 21
Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results. Quarterly Results Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0.03).
Harrow Health Q2 EPS $(0.11) Misses $(0.03) Estimate, Sales $18.10M Beat $15.65M Estimate
10 Aug 21
Earnings, News
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 1000 percent decrease over losses of $(0.01) per share from
Earnings Scheduled For August 10, 2021
10 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.